Real-practice management and treatment of idiopathic multicentric Castleman disease with siltuximab: a collection of clinical experiences
Castleman disease (CD) is a group of lymphoproliferative disorders that share common histopathological features yet have widely different aetiologies, clinical features and grades of severity as well as treatments and outcomes. Siltuximab is currently the only therapy approved by the FDA and EMA for...
Main Authors: | Bernardo Rossini, Nicola Cecchi, Felice Clemente, Maria Rosaria De Paolis, Stefan Hohaus, Vanessa Innao, Mariano Lucignano, Roberto Massaiu, Giovanna Palumbo, Gian Matteo Rigolin, Francesca Gaia Rossi, Luisa Verga, Attilio Guarini |
---|---|
Format: | Article |
Language: | English |
Published: |
BioExcel Publishing Ltd
2024-03-01
|
Series: | Drugs in Context |
Subjects: | |
Online Access: | https://www.drugsincontext.com/real-practice-management-and-treatment-of-idiopathic-multicentric-castleman-disease-with-siltuximab-a-collection-of-clinical-experiences/ |
Similar Items
-
Emerging treatments in Castleman disease – a critical appraisal of siltuximab
by: Koff JL, et al.
Published: (2016-01-01) -
Long-term tolerance and efficacy of siltuximab (anti-IL-6) in a young adult with idiopathic multicentric Castleman disease during COVID-19
by: Helbies Bedier, et al.
Published: (2023-11-01) -
The clinical, laboratory, and radiologic improvement due to siltuximab treatment in idiopathic multicentric Castleman’s disease
by: Gi-June Min, et al.
Published: (2021-03-01) -
Impact of siltuximab on patient-related outcomes in multicentric Castleman’s disease
by: Sitenga J, et al.
Published: (2018-01-01) -
TAFRO Syndrome and Elusive Diagnosis of Idiopathic Multicentric Castleman Disease Treated with Empiric Anti-Interleukin-6 Therapy
by: Corinne Williams, et al.
Published: (2021-09-01)